These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9878015)

  • 1. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
    Rinaldo CR; Liebmann JM; Huang XL; Fan Z; Al-Shboul Q; McMahon DK; Day RD; Riddler SA; Mellors JW
    J Infect Dis; 1999 Feb; 179(2):329-36. PubMed ID: 9878015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.
    Hirsch M; Steigbigel R; Staszewski S; Mellors J; Scerpella E; Hirschel B; Lange J; Squires K; Rawlins S; Meibohm A; Leavitt R
    J Infect Dis; 1999 Sep; 180(3):659-65. PubMed ID: 10438352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
    J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
    Foudraine NA; Jurriaans S; Weverling GJ; Burger DM; Hoetelmans RM; Roos MT; Maas J; Miedema F; Reiss P; Portegies P; de Wolf F; Lange JM
    Antivir Ther; 2001 Mar; 6(1):55-62. PubMed ID: 11417762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS.
    Chougnet C; Jankelevich S; Fowke K; Liewehr D; Steinberg SM; Mueller BU; Pizzo PA; Yarchoan R; Shearer GM
    J Infect Dis; 2001 Jul; 184(2):201-5. PubMed ID: 11424019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection.
    Malhotra U; Berrey MM; Huang Y; Markee J; Brown DJ; Ap S; Musey L; Schacker T; Corey L; McElrath MJ
    J Infect Dis; 2000 Jan; 181(1):121-31. PubMed ID: 10608758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
    J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
    Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
    J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
    Notermans DW; Pakker NG; Hamann D; Foudraine NA; Kauffmann RH; Meenhorst PL; Goudsmit J; Roos MT; Schellekens PT; Miedema F; Danner SA
    J Infect Dis; 1999 Oct; 180(4):1050-6. PubMed ID: 10479130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
    Hirsch MS; Steigbigel RT; Staszewski S; McMahon D; Fischl MA; Hirschel B; Squires K; DiNubile MJ; Harvey CM; Chen J; Leavitt RY;
    Clin Infect Dis; 2003 Oct; 37(8):1119-24. PubMed ID: 14523778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.
    Dykes C; Najjar J; Bosch RJ; Wantman M; Furtado M; Hart S; Hammer SM; Demeter LM
    J Infect Dis; 2004 Mar; 189(6):1091-6. PubMed ID: 14999613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.
    Seth A; Markee J; Hoering A; Sevin A; Sabath DE; Schmitz JE; Kuroda MJ; Lifton MA; Hirsch MS; Collier AC; Letvin NL; McElrath MJ
    J Infect Dis; 2001 Mar; 183(5):722-9. PubMed ID: 11181148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
    Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
    N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
    Opravil M; Hill AM; DeMasi R; Dawson D
    Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
    Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.
    Binley JM; Schiller DS; Ortiz GM; Hurley A; Nixon DF; Markowitz MM; Moore JP
    J Infect Dis; 2000 Apr; 181(4):1249-63. PubMed ID: 10762561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
    Coplan PM; Cook JR; Carides GW; Heyse JF; Wu AW; Hammer SM; Nguyen BY; Meibohm AR; DiNubile MJ;
    Clin Infect Dis; 2004 Aug; 39(3):426-33. PubMed ID: 15307012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical trial using zidovudine and lamivudine plus indinavir triple therapy in Chinese individuals with human immunodeficiency virus infection].
    Cao Y; Zhang F; Mei S; Li L; Gao M; Ding Y; Cai W
    Zhonghua Nei Ke Za Zhi; 2002 Feb; 41(2):109-13. PubMed ID: 11940307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.